ArticleNeuro-degenerative diseases2010
Impaired neurotransmitter release in Alzheimer's and Parkinson's diseases.
Article in Neuro-degenerative diseases, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 38 citations in OpenAlex.
- Targeting Microglial Phagocytosis for Alzheimer's Disease Management: Natural, Pharmacological, Nanoparticle, and Gene Therapy Approaches.CNS & neurological disorders drug targets · 2026Review
- Smart Contact Lenses as Wearable Ophthalmic Devices for Disease Monitoring and Health Management.Chemical reviews · 2023Review
- Impaired dopamine release in Parkinson's disease.Brain : a journal of neurology · 2023Review
- Skeletal muscle transcriptomics identifies common pathways in nerve crush injury and ageing.Skeletal muscle · 2022Article
- Region-Specific and Age-Dependent Multitarget Effects of Acetylcholinesterase Inhibitor Tacrine on Comprehensive Neurotransmitter Systems.ACS chemical biology · 2022Article
- Article
- Potential therapeutic effects of antagonizing adenosine AMolecular and cellular biochemistry · 2020Article
- Article
- Article
- Network and Pathway-Based Analyses of Genes Associated with Parkinson's Disease.Molecular neurobiology · 2017Article
- Neurodegenerative Disease Related Proteins Have Negative Effects on SNARE-Mediated Membrane Fusion in Pathological Confirmation.Frontiers in molecular neuroscience · 2017Article
- Abnormal Development of Glutamatergic Synapses Afferent to Dopaminergic Neurons of the Pink1(-/-) Mouse Model of Parkinson's Disease.Frontiers in cellular neuroscience · 2016Article
- Hippocampal memory enhancing activity of pine needle extract against scopolamine-induced amnesia in a mouse model.Scientific reports · 2015Article
- Drp1 inhibition attenuates neurotoxicity and dopamine release deficits in vivo.Nature communications · 2014Article
- Leucine-rich repeat kinase 2 regulates Sec16A at ER exit sites to allow ER-Golgi export.The EMBO journal · 2014Article
- LRRK2 regulates synaptogenesis and dopamine receptor activation through modulation of PKA activity.Nature neuroscience · 2014Article
- Function and dysfunction of presenilin.Neuro-degenerative diseases · 2014Review
- Amyloid-β protein modulates insulin signaling in presynaptic terminals.Neurochemical research · 2012Article
- Interactogeneous: disease gene prioritization using heterogeneous networks and full topology scores.PloS one · 2012Article
- Amyloid-independent mechanisms in Alzheimer's disease pathogenesis.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Mutations in several causative genes have been linked to monogenic forms of Alzheimer's disease (AD) or Parkinson's disease (PD). To look for possible common pathogenic mechanisms underlying age-related neurodegeneration in AD and PD, we employed genetic approaches to investigate systematically the roles of these gene products (e.g. presenilins (PS) for AD; Parkin, DJ-1, PINK1 and LRRK2 for PD) in the mouse brain, especially in neural circuits that are particularly vulnerable in AD or PD. Our series of genetic studies revealed that PS play cell type-specific roles in the developing brain with the most prominent function in the maintenance of neural progenitor cells. In the adult cerebral cortex, where the pathogenesis of AD occurs, loss of PS results in progressive memory impairment and age-related neurodegeneration. Specifically, PS are involved in the regulation of long-term potentiation and NMDA receptor functions. Interestingly, our further genetic dissection in the hippocampal Schaeffer collateral pathway highlighted the importance of presynaptic PS in the activity-dependent regulation of glutamate release and long-term potentiation induction via modulation of calcium release from intracellular stores. Intriguingly, our independent genetic analysis of Parkin, DJ-1, PINK1 and LRRK2 showed a common defect in activity-dependent dopamine release caused by PD-linked mutations in these genes. Together, our genetic studies suggest that presynaptic dysfunction might be a converging early pathogenic event before neurodegeneration in AD and PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.